6533b7d8fe1ef96bd126a439

RESEARCH PRODUCT

Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib

Cabibbo GRolle EDe Giorgio MGenco CPressiani TSpada FSacco RFagiuoli S

subject

OncologySorafenibLiver CirrhosisNiacinamidemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.drug_classPyridinesAntineoplastic AgentsGastroenterologyTyrosine-kinase inhibitorsystemic therapyliver cancerLiver diseaseInternal medicinemedicineHumansPharmacology (medical)treatmentbusiness.industryPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsDisease Managementhepatocellular carcinomamedicine.diseasehepatocellular carcinoma sorafenb cirrhosisdigestive system diseasesOncologyTolerabilityHepatocellular carcinomasorafenibLiver functionLiver cancerbusinessmanagementmedicine.drugcirrhosi

description

Sorafenib (Nexavar®, Bayer), a multi-targeted tyrosine kinase inhibitor, was the first systemic agent that demonstrated a significant improvement in the overall survival in patients with advanced hepatocellular carcinoma and well-preserved liver function. This drug is now recommended in patients with advanced hepatocellular carcinoma as first-line therapy and for patients not suitable for locoregional treatment. This brief article, produced by a multidisciplinary panel including specialists in gastroenterology and oncology, provides an overview of the major issues related to systemic treatment of hepatocellular carcinoma with sorafenib, including staging and prognostic strategies, assessment of liver disease and its complications, and efficacy and safety of this molecule. Particular emphasis is given on how to improve tolerability of sorafenib in difficult-to-treat patients.

yearjournalcountryeditionlanguage
2011-01-01
10.1586/era.11.139http://hdl.handle.net/10281/354284